| 代码 名称 | 现价 | 涨跌 涨幅↓ | | --- | --- | --- | | 300255 常山药业 | 13.78 | +2.30 +20.03% | | 300363 博腾股份 | 29.64 | +4.18 +16.42% | | 002038 双鹭药业 | 11.74 | +1.07 +10.03% | | 000813 德展健康 | 4.54 | +0.41 +9.93% | | 688166 博瑞医药 | 29.39 | +2.29 +8.45% | | 688076 诺泰牛物 | 39.66 | +2.97 +8.09% | | 301393 吴帆生物 | 78.79 | +4.59 +6.19% | | 600721 百花医药 | 8.47 | +0.47 +5.88% | | 605116 奥锐特 | 23.01 | +1.20 +5.50% | | 301092 争光股份 | 32.62 | +1.24 =+1.95% | 自9月8日以来，医药各细分板块进入稳步上行阶段，其中涨幅最大的减肥药板块，14个交易日内涨超 22%。 今日，医药板块情绪格外高涨。 A股方面，CRO概念 ...

Core Insights - Jiangsu's total electricity consumption from January to April reached 264.08 billion kWh, marking a year-on-year increase of 2.2% [1] - The manufacturing of biopharmaceuticals saw a significant electricity consumption increase of 22.3%, while internet data services surged by 42.4%, and wind energy equipment manufacturing skyrocketed by 52.5% [1] - State Grid Jiangsu Electric Power has implemented various measures to enhance service levels and optimize the business environment, contributing to Jiangsu's economic resilience [1] Group 1: Industry Development - Jiangsu Tianke Heda Semiconductor Co., a major global producer of silicon carbide chips, benefits from a tailored energy service strategy by State Grid Xuzhou Power Supply Company, enhancing power reliability and efficiency [2] - The "one industry, one policy" approach has been adopted in multiple cities, including Nanjing and Suzhou, to support industrial clusters with reliable and green electricity [2] - The implementation of smart management systems in companies like Enhua Pharmaceutical and Jiangsu Normal University has led to energy savings of over 25% [2] Group 2: Project Execution - The completion of a 110 kV capacity expansion project for Zhongjian Technology Co. demonstrates the effective "electric butler" service model, which includes personalized project plans and close collaboration with local governments [3] - State Grid Jiangsu Electric Power has supported 36 key provincial projects, successfully delivering electricity to 24 of them, while reducing connection times by over 30 working days [3] - The launch of Zhongbi's second-phase lithium battery project, with a planned capacity of 27 GWh, showcases the efficient service mechanisms in place for major projects [4] Group 3: Community and Infrastructure - The "open door charging pile" service model introduced by State Grid Nantong Power Supply Company addresses the charging difficulties in old residential areas, significantly reducing installation times [6] - The initiative allows residents to complete the charging pile installation process in just five days, streamlining the approval process through community collaboration [6] - Over 70 old residential communities in Nantong have completed upgrades, with the company aiming to enhance the city's status as a friendly environment for electric vehicles [7] Group 4: Overall Impact - State Grid Jiangsu Electric Power has constructed over 18,000 public charging piles, achieving full coverage in towns and highway service areas, facilitating green travel [7] - The company's efforts span from empowering industrial clusters to enhancing the business environment and improving public welfare, contributing significantly to Jiangsu's modernization efforts [7]

Market Overview - The pharmaceutical and biotechnology index increased by 1.50% over the past two weeks, underperforming the CSI 300 index by 0.06 percentage points and the ChiNext index by 2.80 percentage points, ranking 16th among 31 sub-industries, indicating average performance [3] - The Hong Kong Hang Seng Healthcare Index decreased by 1.48%, underperforming the Hang Seng China Enterprises Index by 4.31 percentage points [3] Company R&D Progress Tracking - Recent clinical application advancements include: - BeiGene's BG-C9074 and East China Pharmaceutical's HDM2005 are in the new application stage - BeiGene's BGB-45035 tablet has a new IND application - Enhua Pharmaceutical's NH600001 and Baillie Tianheng's BL-M07D1 are in Phase III clinical trials - Yifang Biotech's D-2570 is in Phase II clinical trials - Haosen Pharmaceutical's HS-20118 is in Phase I clinical trials [4] Investment Outlook - The company is optimistic about the domestic substitution of high-end reagents in the upstream life sciences sector, driven by multiple factors including: - Strong product quality as a foundation for domestic substitution - Emerging downstream demands such as anti-tumor and CAR-T therapies providing opportunities for domestic and foreign competition - Policy support facilitating domestic substitution - The increasing emphasis on supply chain security amid rising de-globalization trends acting as a catalyst for domestic substitution [5] 2025 Annual Investment Strategy - The company emphasizes the need to reshape underlying logic and identify investment opportunities from a payment perspective, considering complex trends in population structure, policy frameworks, and economic environments - The core contradiction lies in the willingness to pay versus the ability to pay, leading to a structured selection of investment opportunities [6][7] Payment Channels Analysis - The company identifies three main payment channels within the pharmaceutical industry: - Hospital payments supported by policies (innovative drugs and devices) - Out-of-pocket payments driven by expanding public demand (blood products, home medical devices, weight loss drug supply chain) - Increasing overseas payment cycles (heparin, respiratory joint inspections) [7]

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology sector [5]. Core Viewpoints - The report is optimistic about the domestic substitution of high-end reagents in the upstream life sciences sector, driven by factors such as product quality, emerging demands in oncology and CAR-T therapies, policy support, and the increasing emphasis on supply chain security amid rising global protectionism [2][24]. Summary by Sections Market Review - Over the past two weeks, the pharmaceutical and biotechnology index increased by 1.50%, underperforming the CSI 300 index by 0.06 percentage points and the ChiNext index by 2.80 percentage points, ranking 16th among 31 sub-industries [1][17]. - The Hong Kong Hang Seng Healthcare Index fell by 1.48%, lagging behind the Hang Seng China Enterprises Index by 4.31 percentage points [1][17]. Company Updates - Recent clinical application updates include new undertakings for injectable BG-C9074 by BeiGene and HDM2005 by Huadong Medicine, as well as IND applications for BGB-45035 tablets by BeiGene [27]. - Companies such as Enhua Pharmaceutical and Bide Pharmaceutical are currently in Phase III clinical trials for NH600001 and BL-M07D1, respectively [27]. Investment Recommendations - The report suggests focusing on companies like Titan Technology, Novozymes, Aladdin, Bide Pharmaceutical, Baipusais, and Yiqiao Shenzhou, which are well-positioned to benefit from the domestic substitution trend in high-end life science reagents [2][24]. Financial Forecasts and Valuations - Key company forecasts include: - Hengrui Medicine: EPS of 1.07 in 2025E with a PE of 48, rated as "Accumulate" [4]. - Mindray Medical: EPS of 10.62 in 2025E with a PE of 22, rated as "Buy" [4]. - United Imaging Healthcare: EPS of 2.39 in 2025E with a PE of 59, rated as "Buy" [4]. - Yuyue Medical: EPS of 2.32 in 2025E with a PE of 15, rated as "Buy" [4].

Group 1 - The fentanyl concept index rose by 0.80%, ranking second among concept sectors, with four stocks increasing in value, including Botao Bio, Lingrui Pharmaceutical, and China National Pharmaceutical Group, which rose by 4.83%, 1.61%, and 1.05% respectively [1] - The leading decliners in the fentanyl sector included Wanfu Biology, Enhua Pharmaceutical, and Renfu Pharmaceutical, which fell by 0.71%, 0.31%, and 0.14% respectively [1] - The overall market saw a net outflow of 0.20 billion yuan from the fentanyl concept sector, with Lingrui Pharmaceutical receiving the highest net inflow of 10.09 million yuan [1] Group 2 - The top stocks in the fentanyl concept based on net capital flow included Lingrui Pharmaceutical with a 1.61% increase and a turnover rate of 0.88%, while Dongfang Bio and Enhua Pharmaceutical experienced slight declines [1] - The net capital outflow for Wanfu Biology and Renfu Pharmaceutical was significant, with outflows of 29.31 million yuan and 66.75 million yuan respectively [1] - The overall performance of the fentanyl concept was contrasted with other sectors, such as the ST sector which rose by 1.11%, while storage chips and DRG/DIP sectors saw declines of 2.67% and 2.66% respectively [1]

证券代码：002262 证券简称：恩华药业 公告编号：2025-029 江苏恩华药业股份有限公司 关于续聘吴继业担任公司证券事务代表的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导性陈述 或者重大遗漏。 江苏恩华药业股份有限公司（以下简称：公司）第七届董事会第一次会议于 2025 年 5 月 7 日在徐州市经济技术开发区龙湖西路 31 号恩华科技大厦 20 楼会议室召开，会议审议通过 了《关于续聘证券事务代表的议案》。 鉴于现任证券事务代表吴继业自担任公司证券事务代表以来，能够严格按照《公司法》 《证券法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》及 《公司章程》等相关规章制度的要求，勤勉尽责地履行了证券事务代表的职责。吴继业先生 近三年未受过中国证监会及其他有关部门的处罚和证券交易所纪律处分；未因涉嫌犯罪被司 法机关立案侦查或者涉嫌违法违规被中国证监会立案稽查，尚未有明确结论；未曾被中国证 监会在证券期货市场违法失信信息公开查询平台公示或者被人民法院纳入失信被执行人名单； 亦不存在被深圳证券交易所认定不适合担任公司证券事务代表的其他情形，任职资格符 ...

证券代码：002262 证券简称：恩华药业 公告编号：2025-028 江苏恩华药业股份有限公司 关于续聘段保州担任公司董事会秘书兼任副总经理的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导性陈 述或者重大遗漏。 江苏恩华药业股份有限公司（以下简称：公司）第七届董事会第一次会议于 2025 年 5 月 7 日在徐州市经济技术开发区龙湖西路 31 号恩华科技大厦 20 楼会议室召开，会议审议通 过了《关于续聘董事会秘书兼任副总经理的议案》。 鉴于现任董事会秘书兼任副总经理段保州自担任公司董事会秘书以来，能够严格按照 《公司法》《证券法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规 范运作》及《公司章程》等相关规章制度的要求，积极工作，勤勉尽责。段保州先生近三年 未受过中国证监会及其他有关部门的处罚和证券交易所纪律处分；未因涉嫌犯罪被司法机关 立案侦查或者涉嫌违法违规被中国证监会立案稽查，尚未有明确结论；未曾被中国证监会在 证券期货市场违法失信信息公开查询平台公示或者被人民法院纳入失信被执行人名单；不存 在《公司法》《深圳证券交易所上市公司自律监管指引第 1 号— ...

证券代码：002262 证券简称：恩华药业 公告编号：2025-030 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 一、监事会会议召开情况 江苏恩华药业股份有限公司 第七届监事会第一次会议决议公告 江苏恩华药业股份有限公司（以下简称：公司）监事会于2025年4月25日以电子邮件 及专人送达的方式向全体监事发出召开第七届监事会第一次会议的通知及相关会议资料。 2025年5月7日上午11：30至12：00，第七届监事会第一次会议在徐州市经济技术开发区 龙湖西路31号恩华科技大厦20楼会议室以现场表决的方式召开，公司3名监事全部参加了 会议。本次会议由监事王丰收先生主持。本次会议的召集、召开程序符合有关法律法规 和公司章程的规定。 二、监事会会议审议情况 1、会议以3票赞成、0票反对、0票弃权的表决结果审议通过了《关于选举公司第七 届监事会主席的议案》。 与会监事一致选举王丰收为公司第七届监事会主席，任期与本届监事会相同。 王丰收简历详见附件。 王丰收先生，1961 年 11 月出生，中国国籍，无境外居留权，中共党员，经济管理专 业本科学历。1980 年 12 月起 ...

证券代码：002262 证券简称：恩华药业 公告编号：2025-027 江苏恩华药业股份有限公司 第七届董事会第一次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 一、董事会会议召开情况 江苏恩华药业股份有限公司（以下简称：公司）第七届董事会第一次会议于2025年5 月7日在徐州市经济技术开发区龙湖西路31号恩华科技大厦20楼会议室召开，会议通知已 于2025年4月25日以专人送达、传真、电子邮件等方式送达给全体董事、监事和高级管理 人员。本次会议应到董事8名，实到董事8名。公司监事和高级管理人员亦列席本次会议。 本次会议由董事长孙彭生先生召集并主持。本次会议的召集、召开程序符合有关法律法 规和公司章程的规定。 二、董事会会议审议情况 1、会议以8票赞成、0票反对、0票弃权的表决结果审议通过了《关于选举公司第七 届董事会董事长的议案》。 同意选举孙彭生担任公司第七届董事会董事长，任期与第七届董事会任期一致。孙 彭生的简历详见附件一。 2、会议以8票赞成、0票反对、0票弃权的表决结果审议通过了《关于选举公司第七 届董事会各专门委员会委员的议案》。 经公 ...

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [8][29]. Core Insights - The industry is experiencing a return to normal growth, with a notable performance in chemical pharmaceuticals, while the overall revenue growth for 2024 is projected to decline by 0.6% year-on-year, marking the first decline in recent years [12][14]. - The report highlights a significant disparity among sectors, with chemical pharmaceuticals showing a remarkable net profit growth of 97.7%, while biological products face substantial short-term performance pressure [17][18]. - The current low allocation and valuation levels present a high cost-performance ratio for investments in the pharmaceutical sector, suggesting it is an excellent time to allocate resources [19][28]. Summary by Sections 1. Innovation in the Pharmaceutical Chain - The report notes that the impact of national procurement and anti-corruption measures is gradually diminishing, leading to a normal release of rigid demand in hospitals [11]. - The overall revenue growth for the industry in 2024 is projected at -0.6%, with net profit and non-recurring net profit declining by 8.1% and 5.9% respectively [12][13]. 2. Investment Recommendations - The report suggests focusing on the innovation drug supply chain (Biotech + CXO + upstream) and certain overseas medical devices, recommending companies such as Aosaikang, Yifang Bio, and WuXi AppTec for investment [29]. - For in-hospital products (traditional Chinese medicine, chemical pharmaceuticals, and medical devices), companies like Hengrui Medicine and Mindray Medical are highlighted as having more certain growth prospects [29]. 3. Market Positioning - The report indicates that the allocation of public fund products in pharmaceutical stocks has decreased from 11.2% in Q1 2024 to 8.7% in Q4 2024, with a slight recovery to 9.1% by Q1 2025 [19][21]. - The pharmaceutical sector's price-to-earnings ratio is at a 10-year low, suggesting potential for growth as innovative products continue to emerge [22][24].